Hematology · AnticoagulantTrial Updateclinicalmid-term

AstraZeneca Investigates Safety of Ondexxya IV Injection in Real-World Use

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AstraZeneca122 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/8/2026, 6:32:35 PM

Assessment confidence: 91% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The ongoing investigation by AstraZeneca into the safety and effectiveness of Ondexxya IV Injection is crucial as it may yield data that impacts the drug's competitive positioning within the anticoagulant market. Monitoring the results will be essential for understanding potential shifts in market viability and regulatory compliance. Regulatory context from FDA (Real-World Evidence Submissions to the Center for Drug Evaluation and Research) supports the near-term read. Assessment grounded in 19 ranked evidence items (19 high-relevance).

Strategic Assessment

Portfolio teams should monitor the outcomes of this survey to gauge Ondexxya's market viability and safety profile. The strongest clinical anchor is Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation) (ClinicalTrials.gov), entity match (astrazeneca). In Hematology · Anticoagulant, 7 regulatory and 1 competitive items passed relevance filtering for AstraZeneca.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (astrazeneca). This investigation may provide critical safety data that could influence the competitive positioning of Ondexxya against other anticoagulants.

Regulatory Outlook

Regulatory risk is concentrated around Real-World Evidence Submissions to the Center for Drug Evaluation and Research (FDA). Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (pdufa). Relevant agencies in corpus: FDA, MHRA. Depending on the findings, there may be implications for Ondexxya's labeling and compliance with safety standards, which could influence future regulatory approvals.

Key Risks

Elevated medium regulatory exposure for AstraZeneca could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The outcomes of this survey could affect Ondexxya's market share and revenue potential, particularly if safety concerns arise that could deter prescriber confidence.
Based on viral evolution, increases in seasonal infections, and facilitation of delivery, an annual combination vaccine simultaneously targeting influenza and SARS-CoV-2 would benefit public health.
Upside for AstraZeneca may improve if Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (ClinicalTrials.gov) delivers favorable follow-through.
Upside for AstraZeneca may improve if An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should monitor the outcomes of this survey to gauge Ondexxya's market viability and safety profile.

What Would Change This Assessment

This becomes more urgent if Results from the safety and effectiveness survey and any subsequent regulatory implications.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Real-World Evidence Submissions to the Center for Drug Evaluation and Research
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (pdufa)
FDA document
View source
Real-World Evidence Submissions to the Center for Biologics Evaluation and Research & the Center for Drug Evaluation and Research
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (pdufa)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
Class 4 Medicines Defect Notification: Brancaster Pharma Limited, Benzylpenicillin benzathine 1.2 Million I.U. and 2.4 Million I.U. powder for suspension for injection, EL(26)A/30
MHRAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)
ClinicalTrials.govhigh relevance
Entity match (astrazeneca)
FDA document
View source
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Effect of Participating in Study of Causes of Pregnancy Loss on Mental Health Outcomes: A Target Trial Emulation Using the COPL Cohort and Danish National Registries
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
A Clinical Study on the Safety and Efficacy of Wide-Band Ultrasound Combined With Traditional Chinese Medicine Preparations in the Prevention and Treatment of Keloids
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Safety and immunogenicity of COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AstraZeneca
Ondexxya

Commercial impact

medium

The outcomes of this survey could affect Ondexxya's market share and revenue potential, particularly if safety concerns arise that could deter prescriber confidence.

Regulatory impact